A Phase 2 interventional study of lisdexamfetamine dimesylate (SPD489) and lisdexamfetamine dimesylate (SPD489) in Binge Eating Disorder, sponsored by Shire. Completed at 31 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.
Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 13th largest by enrollment of the 112 interventional ones that give a count, is the only one that started in 2011, is one of 14 in phase 2, and was the 26th registered.
233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.
Browse Binge-Eating Disorder studies →20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:
Lindner Center of HOPE · Sites in United States
Ages up to 18
Trustees of Dartmouth College · Sites in United States
Ages 18–70
University of Kansas · Sites in United States
Ages 18–65
University of Oklahoma · Sites in United States
Ages 18–120
Milton S. Hershey Medical Center · Sites in United States
Ages 12–26
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 27 · Phase 3 25 · Phase 4 3
First in 1994; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 271 is above the median of 77 across 190 interventional studies indexed under Binge-Eating Disorder.
Median enrollment 67 across the 112 interventional studies, 224 across the 8 observational. Of the 89 that completed or were terminated, 34 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 122 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 6 studies filed under Binge-Eating Disorder — fewer than ten, so there is no comparison to draw.
12 of the studies in Binge-Eating Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413433Phase 3Axsome Therapeutics, Inc.Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | 2026-12 |
| NCT06858774Icahn School of Medicine at Mount SinaiUse of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder | 2026-11 |
| NCT06485687Ali RezaiLow Intensity Focused Ultrasound for Binge Eating Disorder | 2026-12-31 |
| NCT05664516Massachusetts General HospitalA Study of the Effects of Oxytocin in Adults With Binge-eating Disorder | 2027-01 |
| NCT03393039University of California, San DiegoEffects of Negative Affect in Individuals With Binge Eating Episodes | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 122 studies in Binge-Eating Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: lisdexamfetamine dimesylate (SPD489)
Drug: lisdexamfetamine dimesylate (SPD489)
Drug: lisdexamfetamine dimesylate (SPD489)
Drug: Placebo
SPD489-30mg capsules taken once daily for up to 11 weeks
Also known as: LDX, Vyvanse
SPD489 50mg capsules taken once-daily for up to 11 weeks
Also known as: LDX, Vyvanse
SPD489 70mg capsule taken once-daily for up to 11 weeks
Also known as: LDX, Vyvanse
Placebo capsule taken once daily for up to 11 weeks
Change From Baseline in Log Transformed Binge Days Per Week at Week 11
Binge day is defined as a day during which at least 1 binge episode occurs.
Time frame: Baseline and week 11
Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks
The number of binge episodes per week as assessed by clinical interview based on subject diary.
Time frame: Baseline and up to 11 weeks
1-Week Binge Response, Last Observation Carried Forward (LOCF)
The 1-week binge response was defined as either a 1-week remission (a 100% reduction of binge episodes from baseline \[ie, a cessation of binge eating behavior\]), or a marked response (75 to \<100% reduction in binge episodes from baseline), or a moderate response (50 to \<75% reduction in binge episodes from baseline), or a negative/minimal response (\<50% reduction in binge episodes from baseline). The 1-week response was determined at the end of the study utilizing a LOCF approach.
Time frame: Last 7 days on study
4-Week Binge Response
Subjects are free from binge episodes for 4 weeks.
Time frame: Last 28 days on study
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Baseline
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: up to 11 weeks
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Up to 11 weeks
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11
The YBOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. A score of 0-7 is sub-clinical; 8-15 is mild; 16-23 is moderate; 24-31 is severe; and 32-40 is extreme.
Time frame: Baseline and week 11
Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: Baseline and week 11
Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11
The HAM-A is a rating scale developed to quantify the severity of anxiety symptomatology. It consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe, and 31-56 severe anxiety.
Time frame: Baseline and week 11
Change From Baseline in Eating Inventory Score at Week 11
The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior: cognitive restraint of eating, disinhibition, and hunger. Cognitive restraint of eating consists of 20 items, disinhibition consists of 16 items, and hunger consists of 15 items. Each item scores either 0 or 1 point for a total score of 0-20 for cognitive restraint of eating, 0-16 for disinhibition, and 0-15 for hunger. A higher score is better for cognitive restraint of eating and lower scores are better for disinhibition and hunger.
Time frame: Baseline and week 11
Change From Baseline in Binge Eating Scale (BES) Score at Week 11
The BES is a 16-item self-reported questionnaire that is designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. The items are summed, with possible scores ranging from 0 to 46. A score of 27 or higher indicates severe binge-eating problems, and a score of 17 or lower designates no binge-eating problems.
Time frame: Baseline and week 11
Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11
The BIS-11 is a self-reported 30-item questionnaire that measures impulsiveness using a 4-point Likert scale (rarely/never = 1, occasionally = 2, often = 3, almost always/always = 4). A Total Impulsivity score is calculated by summing the scores for each item. Possible scores range from 30 - 120. Higher scores indicate increased impulsiveness.
Time frame: Baseline and week 11
Change From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11
The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. There are 8 subscales. Four of the subscales has one-item each; the other 4 have two-items each. For each subscale, a mean value was first computed and transformed to a position on a scale ranging from 0-100 (Z-transformation). The aggregate total scores are then transformed into a mean value ranging from 0 (lowest level of health) to 100 (highest level of health).
Time frame: Baseline and week 11
| Milestone | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Started | 64 | 66 | 65 | 65 |
| Completed | 47 | 51 | 52 | 52 |
| Not completed | 17 | 15 | 13 | 13 |
| Withdrew: Adverse event | 0 | 3 | 1 | 3 |
| Withdrew: Protocol violation | 7 | 2 | 2 | 5 |
| Withdrew: Withdrawal by subject | 6 | 4 | 4 | 2 |
| Withdrew: Lost to follow-up | 4 | 6 | 3 | 2 |
| Withdrew: Unable to meet visit schedule | 0 | 0 | 1 | 0 |
| Withdrew: Lack of compliance | 0 | 0 | 0 | 1 |
| Withdrew: Subject was unblinded | 0 | 0 | 1 | 0 |
| Withdrew: Excluded therapy | 0 | 0 | 1 | 0 |
Binge day is defined as a day during which at least 1 binge episode occurs.
| Log days | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Change From Baseline in Log Transformed Binge Days Per Week at Week 11 | -1.23 ± 0.069 | -1.24 ± 0.067 | -1.49 ± 0.066 | -1.57 ± 0.067 |
The number of binge episodes per week as assessed by clinical interview based on subject diary.
| Binge Episodes | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks | -4.07 ± 2.718 | -4.57 ± 3.266 | -5.10 ± 3.026 | -5.09 ± 2.586 |
The 1-week binge response was defined as either a 1-week remission (a 100% reduction of binge episodes from baseline \[ie, a cessation of binge eating behavior\]), or a marked response (75 to \<100% reduction in binge episodes from baseline), or a moderate response (50 to \<75% reduction in binge episodes from baseline), or a negative/minimal response (\<50% reduction in binge episodes from baseline). The 1-week response was determined at the end of the study utilizing a LOCF approach.
| Participants | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| 1 week remission | 23 | 28 | 33 | 35 |
| Marked response | 15 | 20 | 24 | 23 |
| Moderate response | 13 | 8 | 4 | 1 |
| Negative/Minimal response | 11 | 10 | 3 | 4 |
Subjects are free from binge episodes for 4 weeks.
| Participants | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| 4-Week Binge Response | 13 | 22 | 27 | 31 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percentage of participants | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Normal, not at all ill | 0 | 0 | 0 | 0 |
| Borderline mentally ill | 0 | 0 | 0 | 1.6 |
| Mildly ill | 1.6 | 0 | 3.1 | 1.6 |
| Moderately ill | 56.5 | 54.5 | 59.4 | 42.9 |
| Markedly ill | 29.0 | 30.3 | 29.7 | 47.6 |
| Severely ill | 11.3 | 12.1 | 6.3 | 6.3 |
| Among the most extremely ill | 1.6 | 3.0 | 1.6 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percentage of participants | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Normal, not at all ill | 37.1 | 55.4 | 60.9 | 65.1 |
| Borderline mentally ill | 19.4 | 26.2 | 23.4 | 20.6 |
| Mildly ill | 12.9 | 1.5 | 6.3 | 11.1 |
| Moderately ill | 24.2 | 13.8 | 7.8 | 3.2 |
| Markedly ill | 6.5 | 1.5 | 1.6 | 0 |
| Severely ill | 0 | 0 | 0 | 0 |
| Among the most extremely ill | 0 | 1.5 | 0 | 0 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| Percentage of participants | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks | 64.5 | 84.6 | 90.6 | 93.7 |
The YBOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. A score of 0-7 is sub-clinical; 8-15 is mild; 16-23 is moderate; 24-31 is severe; and 32-40 is extreme.
| units on a scale | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11 | -12.0 ± 0.87 | -15.0 ± 0.84 | -15.3 ± 0.83 | -17.0 ± 0.83 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
| units on a scale | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11 | -1.7 ± 0.35 | -1.9 ± 0.34 | -1.3 ± 0.33 | -1.6 ± 0.33 |
The HAM-A is a rating scale developed to quantify the severity of anxiety symptomatology. It consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe, and 31-56 severe anxiety.
| units on a scale | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11 | -1.5 ± 0.30 | -0.9 ± 0.29 | -1.1 ± 0.29 | -0.6 ± 0.29 |
The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior: cognitive restraint of eating, disinhibition, and hunger. Cognitive restraint of eating consists of 20 items, disinhibition consists of 16 items, and hunger consists of 15 items. Each item scores either 0 or 1 point for a total score of 0-20 for cognitive restraint of eating, 0-16 for disinhibition, and 0-15 for hunger. A higher score is better for cognitive restraint of eating and lower scores are better for disinhibition and hunger.
| units on a scale | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Cognitive restraint of eating | 2.5 ± 0.65 | 4.4 ± 0.62 | 3.8 ± 0.61 | 4.3 ± 0.62 |
| Disinhibition | -3.8 ± 0.58 | -5.6 ± 0.56 | -6.3 ± 0.55 | -7.2 ± 0.56 |
| Hunger | -3.3 ± 0.58 | -5.3 ± 0.56 | -6.0 ± 0.55 | -7.8 ± 0.56 |
The BES is a 16-item self-reported questionnaire that is designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. The items are summed, with possible scores ranging from 0 to 46. A score of 27 or higher indicates severe binge-eating problems, and a score of 17 or lower designates no binge-eating problems.
| units on a scale | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Change From Baseline in Binge Eating Scale (BES) Score at Week 11 | -12.2 ± 1.28 | -16.1 ± 1.25 | -17.6 ± 1.24 | -20.6 ± 1.24 |
The BIS-11 is a self-reported 30-item questionnaire that measures impulsiveness using a 4-point Likert scale (rarely/never = 1, occasionally = 2, often = 3, almost always/always = 4). A Total Impulsivity score is calculated by summing the scores for each item. Possible scores range from 30 - 120. Higher scores indicate increased impulsiveness.
| units on a scale | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11 | -3.1 ± 1.09 | -5.8 ± 1.05 | -5.2 ± 1.05 | -6.9 ± 1.05 |
The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. There are 8 subscales. Four of the subscales has one-item each; the other 4 have two-items each. For each subscale, a mean value was first computed and transformed to a position on a scale ranging from 0-100 (Z-transformation). The aggregate total scores are then transformed into a mean value ranging from 0 (lowest level of health) to 100 (highest level of health).
| units on a scale | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Aggregate Physical Score | 1.3 ± 0.78 | 2.6 ± 0.75 | 2.4 ± 0.74 | 3.9 ± 0.75 |
| Aggregate Mental Score | 4.9 ± 1.03 | 5.0 ± 1.00 | 5.5 ± 0.99 | 4.9 ± 1.00 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/63 (0%) | 37/63 (58.7%) |
| Lisdexamfetamine Dimesylate (SPD489) 30 mg | — | 2/66 (3%) | 57/66 (86.4%) |
| Lisdexamfetamine Dimesylate (SPD489) 50 mg | — | 0/65 (0%) | 56/65 (86.2%) |
| Lisdexamfetamine Dimesylate (SPD489) 70 mg | — | 1/65 (1.5%) | 53/65 (81.5%) |
| Event | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Drug toxicityInjury, poisoning and procedural complications | 0/63 | 0/66 | 0/65 | 1/65 |
| Pancreatitis acuteGastrointestinal disorders | 0/63 | 1/66 | 0/65 | 0/65 |
| AppendicitisInfections and infestations | 0/63 | 1/66 | 0/65 | 0/65 |
| Event | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg |
|---|---|---|---|---|
| Dry mouthGastrointestinal disorders | 5/63 | 22/66 | 22/65 | 27/65 |
| Decreased appetiteMetabolism and nutrition disorders | 4/63 | 17/66 | 13/65 | 12/65 |
| InsomniaPsychiatric disorders | 1/63 | 7/66 | 10/65 | 9/65 |
| HeadacheNervous system disorders | 6/63 | 9/66 | 9/65 | 5/65 |
| NasopharyngitisInfections and infestations | 2/63 | 8/66 | 1/65 | 3/65 |
| NauseaGastrointestinal disorders | 0/63 | 5/66 | 6/65 | 4/65 |
| Weight decreasedInvestigations | 1/63 | 2/66 | 4/65 | 6/65 |
| ConstipationGastrointestinal disorders | 1/63 | 6/66 | 3/65 | 5/65 |
| DiarrheaGastrointestinal disorders | 0/63 | 4/66 | 5/65 | 1/65 |
| Feeling jitteryGeneral disorders | 0/63 | 1/66 | 3/65 | 5/65 |
Safety Analysis Set defined as all randomized subjects who had taken at least 1 dose of investigational product and who had at least 1 follow-up safety assessment completed. One subject in the Placebo group did not have a post-baseline safety assessment and was excluded from the safety population (n=259).
| Age, Continuous(years) | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg | Total |
|---|---|---|---|---|---|
| Mean | 38.0 ± 10.30 | 38.4 ± 11.14 | 39.6 ± 9.32 | 38.6 ± 10.01 | 38.7 ± 10.17 |
| Age, Customized(Participants) | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg | Total |
|---|---|---|---|---|---|
| 18-39 years | 35 | 35 | 30 | 34 | 134 |
| 40-55 years | 28 | 31 | 35 | 31 | 125 |
| Sex: Female, Male(Participants) | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg | Total |
|---|---|---|---|---|---|
| Female | 49 | 57 | 50 | 55 | 211 |
| Male | 14 | 9 | 15 | 10 | 48 |
| Region of Enrollment(Participants) | Placebo | Lisdexamfetamine Dimesylate (SPD489) 30 mg | Lisdexamfetamine Dimesylate (SPD489) 50 mg | Lisdexamfetamine Dimesylate (SPD489) 70 mg | Total |
|---|---|---|---|---|---|
| United States | 63 | 66 | 65 | 65 | 259 |
Ran from May 2011 to primary completion in Jan 2012, 8 months.
Results were first posted in Dec 2012, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine